Real-world time on treatment (rwTOT) with first-line (1L) enfortumab vedotin and pembrolizumab (EV+P) after U.S. Food and Drug Administration approval for advanced urothelial cancer (aUC).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Melanie Mayer, Nicholas Seewald, Ernesto Ulloa Perez, Blanca Homet Moreno, Chethan Ramamurthy, Aram Babcock, Haojie Li, Ronac Mamtani
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Merck
OpenAlex ID: W4407700097